TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22890641
Drug: Nicardipine prolonged-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine prolonged-release implants (NPRIs) containing 4 mg of nicardipine placed in the cistern of the cerebral arteries during surgery.
Study: 21391429
Drug: Fenofibrate immediate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate immediate release tablets
Study: 19219669
Drug: Pharmacotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy treatment
Study: 19219669
Drug: Initial Urine
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial Urine Drug Screen (UDS) results
Study: 16527634
Drug: Injection molded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection molded elastomeric chains
Study: 12873923
Drug: ondansetron 100
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ondansetron 100 micro g/kg IV
Study: 12873923
Drug: dolasetron 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: dolasetron 350 micro g/kg IV
Study: 12873923
Drug: dolasetron 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: dolasetron 45 micro g/kg IV
Study: 12873923
Drug: dolasetron <350
Approvals — FDA: no, EMA: no, PMDA: no
Description: dolasetron <350 micro g/kg
Study: 1928657
Drug: Antigen-antibody complexes
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antigen-antibody complexes at different ratios and dosages
Study: 1928657
Drug: Antigen-antibody complexes
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antigen-antibody complexes (previous season treatment)
Study: 6886901
Drug: ORS90 (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORS90 (90 mmol Na/L)
Study: 6886901
Drug: ORS40 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORS40 (40 mmol Na/L)
Study: 26884439
Drug: Insulin deprivation
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin deprivation and endotoxin administration (KET)
Study: 26884439
Drug: Insulin‐controlled euglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin‐controlled euglycemia
Study: 25526951
Drug: Oral granulated
Normalized name: Oral Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral granulated Chinese herbal medicine YXBCM01 plus topical calcipotriol 0.005%
Study: 25526951
Drug: Oral YXBCM01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral YXBCM01 placebo plus topical calcipotriol 0.005%
Study: 16335699
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (PUFA) supplementation (3.6 g per day)
Study: 11740718
Drug: Oral itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole (200 mg per day)
Study: 9635614
Drug: Psychiatric treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychiatric treatment in addition to physical treatment (experimental group, N = 86)
Study: 9635614
Drug: Physical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical treatment alone (control group, N = 42)
Study: 9053564
Drug: Pulsed-field gel
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed-field gel electrophoresis (PFGE) of chromosomal DNA fragments
Study: 3180674
Drug: 300 ml
Normalized name: HYQVIA 30 GM / 300 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 ml 50% w/v baritop and effervescent tablets
Study: 3180674
Drug: 300 ml
Normalized name: HYQVIA 30 GM / 300 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 ml 100% w/v baritop with 10 ml of Gastrografin and effervescent tablets
Study: 24206457
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with lisinopril (10 to 40 mg per day)
Study: 24206457
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with losartan (100 mg per day)
Study: 21292243
Drug: Cue-exposure treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cue-exposure treatment (CET)
Study: 19636278
Drug: motavizumab (3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: motavizumab (3, 15, or 30 mg/kg intravenously)
Study: 11383457
Drug: Treatment based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment based on correlation between tumor size and stage of molecular-genetical disorders
Study: 9401505
Drug: Test Diet
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test Diet (TD): a combination of a semi-solid pap (maize flour, black beans, oil) and a liquid gruel, Incaparina (maize flour, cotton seed flour, sugar), in addition to breast-milk and other home foods (n = 45 episodes) for 14 days
Study: 2441156
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of 100 micrograms of alpha‐hANP
Study: 2441156
Drug: Control subcutaneous
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control subcutaneous injection (placebo)
Study: 2697238
Drug: Control solution
Normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solution in sitting position
Study: 2697238
Drug: Control solution
Normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solution in supine position
Study: 24228867
Drug: Physiotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy and occupational therapy delivered six days a week (Monday through Saturday)
Study: 24228867
Drug: Physiotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy and occupational therapy delivered five days a week (Monday through Friday)
Study: 21604466
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment with clarithromycin, alkaline nasal douche, and intranasal mometasone furoate for 12 weeks
Study: 21604466
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (adenoidectomy, tonsillectomy, or ESS)
Study: 11579852
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HOT), administered once daily for 10 days
Study: 11579852
Drug: Intravenous vasodilator,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vasodilator, administered for 10 days
Study: 10999061
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HOT)
Study: 11579852
Drug: Intravenous vasodilator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vasodilator
Study: 10594293
Drug: Topical Skin
Normalized name: Betadine 7.5% Topical Skin Cleanser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Skin Protectant (TSP)
Study: 7970925
Drug: Aerosolized furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolized furosemide (1.0 mg/kg)
Study: 7970925
Drug: Aerosolized albuterol
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized albuterol (0.15 mg/kg)
Study: 7970925
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of albuterol and furosemide
Study: 3297594
Drug: Dihydroxydibutylether (DHBE),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroxydibutylether (DHBE), 900 mg daily
Study: 30071296
Drug: Daily IGRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily IGRT
Study: 30071296
Drug: Weekly IGRT
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly IGRT
Study: 23075398
Drug: Meal preparation
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meal preparation training combined with pedometer-based step count monitoring
Study: 16300696
Drug: Nalbuphine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 0.2 mg/kg
Study: 8554498
Drug: Gemfibrozil (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (1200 mg/day, n = 15)
Study: 8554498
Drug: Pravastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (10 or 20 mg, n = 10 and 4 respectively)
Study: 1785180
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated and inactivated virion divaccines of influenza A (H1N1 + H3N2) and influenza B vaccines
Study: 31453982
Drug: Paracetamol (2660
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (2660 mg total over 2 weeks)
Study: 24755888
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m² d1) and either cisplatin (75 mg/m² d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G)
Study: 24755888
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m² d1) and either cisplatin (75 mg/m² d1) or carboplatin (AUC = 5 d1) plus gefitinib (PC-G)
Study: 19692943
Drug: Evidence based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence based medicine methodology
Study: 19692943
Drug: Vital medicines
Normalized name: Vital-Chlor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vital medicines listing
Study: 19692943
Drug: Lists of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lists of refundable medicines
Study: 15307690
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine 'xiao cuo fang' combined with 0.1% adapalene gel
Study: 15307690
Drug: 0.03% retinoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% retinoic acid cream
Study: 9794097
Drug: Acipimox (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (250 mg/day, four times daily)
Study: 2572038
Drug: Broxaterol (0.6-1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broxaterol (0.6-1.2 mg/day by metered dose inhaler or 0.5-1.5 mg/day orally)
Study: 2572038
Drug: Broxaterol nebulizer
Normalized name: procaterol
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broxaterol nebulizer solution
Study: 2572038
Drug: Broxaterol by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broxaterol by metered dose inhaler
Study: 20912
Drug: Etomidate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 0.3 mg/kg with diazepam and atropine
Study: 20912
Drug: Etomidate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 0.3 mg/kg with papaveretum and hyoscine
Study: 19832806
Drug: Asenapine 5
Normalized name: asenapine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine 5 or 10 mg twice daily
Study: 19832806
Drug: Olanzapine 5
Normalized name: olanzapine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 5 to 20 mg once daily
Study: 15072175
Drug: Interviewer administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer administered CRQ (CRQ-IA)
Study: 15072175
Drug: Self-administered CRQ
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered CRQ (CRQ-SA)
Study: 11299062
Drug: Transfusion to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion to a level of 100 g/l
Study: 9512851
Drug: Granisetron (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (2.5 mg)
Study: 8736239
Drug: 5-micrograms dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-micrograms dose of Pre S recombinant vaccine
Study: 8736239
Drug: 10-micrograms dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-micrograms dose of Pre S recombinant vaccine
Study: 8736239
Drug: Pre S
Normalized name: Pre Sed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre S recombinant vaccine
Study: 7375913
Drug: Ketotifen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (2 mg daily for two or three weeks)
Study: 28904966
Drug: 1 μg/kg oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg/kg oral dexmedetomidine (DEX) in apple juice
Study: 25825013
Drug: Liraglutide treatment
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide treatment (1.8mg/day subcutaneously)
Study: 19761715
Drug: Esomeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (40 mg) + Acetylsalicylic acid (325 mg)
Study: 19761715
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (325 mg) alone
Study: 19761715
Drug: Esomeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (40 mg) alone
Study: 17634483
Drug: Erlotinib 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 50 mg daily in cohort 1
Study: 17634483
Drug: Erlotinib 100
Normalized name: erlotinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 100 mg daily in cohort 2
Study: 17634483
Drug: Erlotinib 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 75 mg daily in cohort 2
Study: 17634483
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg daily in cohort 3
Study: 14990394
Drug: Perindopril-based active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril-based active treatment
Study: 9064950
Drug: Intravenous iloprost
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous iloprost (ILO) 2 ng kg‐1 min‐1
Study: 1473306
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with ramipril 5 mg plus hydrochlorothiazide 25 mg
Study: 1473306
Drug: Ramipril 5
Normalized name: ramipril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 5 mg monotherapy
Study: 6322827
Drug: Topical analgesia
Normalized name: ANALGESIC TOP GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical analgesia (4% lignocaine 2 ml)
Study: 6322827
Drug: Thiopentone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (10 mg kg‐1)
Study: 26561047
Drug: losartan (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan (25 to 50 mg/d)
Study: 15465887
Drug: Ibuprofen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (10 mg/kg oral)
Study: 9205679
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no ibuprofen)
Study: 10705093
Drug: Oral cancer
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cancer information leaflet
Study: 28117270
Drug: Supervised self-injection
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supervised self-injection with an empty syringe
Study: 22276957
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser treatment (KEY Laser(®) 3)
Study: 22276957
Drug: Sonic debridement
Normalized name: Ellis Tonic
DrugBank: Zinc sulfate, unspecified form (DB14548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonic debridement (Sonicflex(®) 2003 L)
Study: 22276957
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Er:YAG laser and Sonic debridement)
Study: 17584198
Drug: Doppler Echo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doppler Echo, Doppler myocardial imaging, Strain rate imaging, transthoracic CFR after dipyridamole infusion, and brachial artery vasodilatation measurement in SSc patients
Study: 17584198
Drug: Serological antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serological antibodies analysis
Study: 9570235
Drug: Active Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Chinese herbal medication (CH-100), five tablets thrice daily
Study: 9570235
Drug: Placebo tablets,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, five tablets thrice daily
Study: 8072815
Drug: Haemophilus influenzae
Normalized name: HAEMOPHILUS INFLUENZAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemophilus influenzae vaccine (tetanus toxoid conjugate) administered concurrently with DTPa and IPV
Study: 3211485
Drug: 1.0% suprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0% suprofen solution
Study: 22591190
Drug: Moderate alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate alcohol dose (intended peak breath alcohol concentration of 0.04%)
Study: 20186830
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide 130 mg/m(2) on Days 1 through 14 every 4 weeks for 12 cycles (C arm)
Study: 20186830
Drug: Levamisole 5
Normalized name: levamisole 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole 5 mg weekly for 48 weeks (levamisole arm)
Study: 20186830
Drug: No systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No systemic therapy (control arm)
Study: 21218747
Drug: Intravenous omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous omeprazole
Study: 7582397
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol treatment
Study: 2092026
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with both amoxycillin and TDB
Study: 25066558
Drug: Mild thrombocytopenia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild thrombocytopenia (nadir platelet count 100-149 × 10(9)/L)
Study: 25066558
Drug: Severe thrombocytopenia
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe thrombocytopenia (nadir platelet count <100 × 10(9)/L)
Study: 18569863
Drug: Prasugrel 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 60 mg loading dose (LD) followed by 10 days of prasugrel 10 mg MD (n = 16)
Study: 18569863
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg MD (n = 19)
Study: 18569863
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg MD (control)
Study: 15779502
Drug: CODAS formulation
Normalized name: CODA-001
DrugBank: CODA-001 (DB14915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CODAS formulation of verapamil (200 mg)
Study: 11867940
Drug: CRH administration
Normalized name: Ovine CRH
DrugBank: Corticorelin ovine triflutate (DB09067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRH administration in obese subjects
Study: 11867940
Drug: CRH administration
Normalized name: Ovine CRH
DrugBank: Corticorelin ovine triflutate (DB09067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRH administration in control subjects
Study: 29803203
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei (108 cfu daily for 8 weeks)
Study: 29803203
Drug: Placebo (maltodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin capsules for 8 weeks)
Study: 10442383
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy combined with pelvic radiation therapy
Study: 7625793
Drug: Cefdinir 200
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefdinir 200 mg
Study: 8707743
Drug: Cefdinir 300
Normalized name: cefdinir 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefdinir 300 mg
Study: 7625793
Drug: Cefdinir 400
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefdinir 400 mg
Study: 8707743
Drug: Cefdinir 600
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefdinir 600 mg
Study: 7625793
Drug: Cefdinir (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefdinir (all doses)
Study: 7625793
Drug: Cefdinir (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefdinir (200 to 400 mg administered twice daily)
Study: 2653046
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids only (Group A)
Study: 2653046
Drug: Topical and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical and systemic corticosteroids (Group B)
Study: 2653046
Drug: Systemic cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic cyclosporine with topical and systemic corticosteroids (Group C)
Study: 31774581
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (inOT)
Study: 30706652
Drug: Itopride 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itopride 50 mg (I50)
Study: 30706652
Drug: Domperidone 10
Normalized name: domperidone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 10 mg (D10)
Study: 30706652
Drug: Itopride 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itopride 100 mg (I100)
Study: 26422095
Drug: Esomeprazole 5
Normalized name: esomeprazole 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 5 or 10 mg daily (<20 kg) or 10 or 20 mg daily (>20 kg) for 8 weeks
Study: 21097785
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% micafungin (MCFG)
Study: 21097785
Drug: Topical 0.2%
Normalized name: coal tar topical 0.2% topical soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.2% fluconazole (FCZ)
Study: 19052139
Drug: PACAP38 infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PACAP38 infusion (10 pmol/kg/min)
Study: 19052139
Drug: PACAP38 infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PACAP38 infusion